Prof. Dr. Markus A. Rüegg is a professor of Neurobiology at the Biozentrum of the University of Basel. He is also the Co-founder and CEO of SEAL Therapeutics Ltd., a biotech company advancing novel gene therapy approaches for laminin-α2 deficient congenital muscular dystrophy (LAMA2-MD). SEAL Therapeutics was founded in 2021 by Prof. Rüegg, Dr. Judith Reinhard, and Dr. Thomas Meier, and is built on two decades of pioneering research by Prof. Rüegg and Prof. Peter Yurchenco. Their innovative SEAL technology uses two engineered linker proteins to compensate for the loss of laminin-α2, with the goal of restoring muscle and nerve function. Prof. Rüegg’s work has significantly shaped the field of neuromuscular disease research and is now being translated toward clinical application.